had significantly worse median QoL scores ($P=0.02$), higher HADS-depression ($P=0.005$) and HADS-anxiety ($P=0.05$). By contrast, in those with quiescent UC, those with an FGID did not have different median HADS scores (depression $P=0.15$, anxiety $P=0.62$) or IBD-QoL scores ($P=0.20$), compared those without FGIDs.

Conclusion This study is one of the first to use Rome IV criteria in UC and confirms that the prevalence of FGIDs is high. Patients with active disease and overlapping functional symptoms appear to have worse QoL and more psychological distress compared to those with quiescent disease. Clinicians should therefore be vigilant to this functional overlap and treat both functional and inflammatory driven symptoms.

OWE-12 FUNGAL FUMES IN FAECES – HIDDEN CULPRIT BEHIND PARKINSON'S DISEASE? A FAECAL METABOLOMICS STUDY

¹Gerum Gashaw Gebeyehu*, ¹Eduardo De Pablo-Fernandez, ¹Rachael Hough, ¹Chris Probert, ¹Anton Emmanuel, ²Tom Warner. ¹UCL Queen Square Institute of Neurology, London, U K; ²University of Liverpool, Liverpool, UK

10.1136/gutjnl-2019-BSGAbstracts.391

Introduction Accumulating evidence implicates the brain gut axis in the pathogenesis of Parkinson's disease (PD). Altered gut permeability may result in afferent vagal transport of an unknown antigen or toxin to the central nervous system, leading to the characteristic dopaminergic neurodegeneration. A study in fruit flies identified the possible role for fungal metabolites, for example 1-octen-3-ol, in a loss of dopamine activity. We investigated the hypothesis that such fungal metabolites might arise from the faeces. We present the results of an evaluation of the faecal metabolome by assessing volatile organic compounds (VOCs) in PD patients.

Methods Using solid phase micro-extraction and gas chromatography and mass spectrometry VOCs were extracted from faecal samples from 35 PD patients (69% male; age 67 ± 8 years; disease duration 11 ± 5 years) and 35 healthy controls (37% male; age 65 ± 8 years). VOCs were identified using automated mass-spectral deconvolution and identification system software and the national institute of standards and technology library. Distinguishing compounds were identified using fold change and t-test and corrected for multiple comparisons; group associations were determined using principal components analysis (PCA) and dendrograms. Findings were compared among groups and correlated with main variables.

Results A mean of 63 VOCs were found from PD samples and 74 from controls ($p < 0.007$). The abundance of VOCs in PD and all controls was compared: 33 differed, 7 of which persisted after correction for multiple comparison, including 2-octanone. PCA showed distinct clustering of groups by disease status (Figure 1). In PD, there was an increased abundance of 2-methyl-6-methylideneoct-2-ene, (6Z)-2,6-dimethylocta-2,6-diene and 7-methyl-3-methylideneocta-1,6-diene and a decreased abundance of cyclohexanecarboxylic acid and methyl pentanoate. Several of the VOCs which increased in PD were fungal metabolites. There was no differences in VOCs in patients compared by disease stage.

Conclusions Metabolomic characterisation in PD patients demonstrates a distinct profile to healthy controls and an increased abundance of fungal metabolites, suggesting a potential role of fungal dysbiosis in PD pathogenesis.

Abstract OWE-12 Figure 1

OWE-13 CONSEQUENCES OF USING THE ROME IV CRITERIA TO DIAGNOSE IRRITABLE BOWEL SYNDROME

^{1,2}Christopher Black*, ^{1,2}Yan Yiannakou, ²Lesley Houghton, ³Alexander Ford. ¹Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK; ²County Durham and Darlington NHS Foundation Trust, Durham, UK; ³Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK

10.1136/gutjnl-2019-BSGAbstracts.392

Introduction There are few studies examining implications of applying the Rome IV criteria for irritable bowel syndrome (IBS), in preference to the previous gold standard, the Rome III criteria. We conducted a cross-sectional survey of over 1000 individuals who self-identified as having IBS in order to examine this issue.

Methods We collected complete demographic, symptom, mood, and psychological health data from 1375 adult subjects in the UK community with IBS. We applied both the Rome III and the Rome IV criteria simultaneously to examine what proportion met each of these diagnostic criteria for IBS. We measured the level of agreement between the Rome III and Rome IV criteria, and assessed for presence of an alternative functional bowel disorder in individuals who no longer met diagnostic criteria for IBS with the more restrictive Rome IV criteria. Finally, we compared characteristics of individuals who met only Rome III criteria with those who met Rome IV criteria.

Results In total, 1080 (78.9%) of 1368 individuals with IBS met the Rome III criteria. In contrast, only 811 (59.1%) of 1373 individuals with IBS met the Rome IV criteria. Agreement between the criteria was only moderate ($\text{Kappa} = 0.50$). The reasons for not meeting the Rome IV criteria for IBS among those meeting the Rome III criteria are shown in Table 1. Of those people no longer meeting Rome IV criteria for IBS, 33 (11.5%) met Rome IV criteria for functional constipation, 118 (41.3%) functional diarrhoea, 68 (23.8%) functional abdominal bloating or distension, and 67 (23.4%) an unspecified functional bowel disorder. This meant that, of those individuals with Rome III IBS who did not meet the Rome IV criteria for IBS, only 11.5% were reclassified into another functional bowel disorder where licensed and evidence-based